로딩 중…
지수 로딩 중…
ToolGen
199800· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩32,000-0.47%
2026-09-18
Financials
Valuation Metrics
ToolGen's Market Cap is ₩2879B. At end of 2025 it was ₩5191B. Ranked #680 of 2,421 in KR market (top 28%), #284 of 1,640 on KOSDAQ (top 17%), #73 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 32%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 287.92B KRW | KR#680/2,421 Sec#73/231 |
| Revenue | 1.91B KRW | KR#2,383/2,421 Sec#216/231 |
| Net Income | -39.12B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 61.65B KRW | KR#2,087/2,421 Sec#182/231 |
| Net Assets | 55.85B KRW | KR#1,829/2,421 Sec#154/231 |
| Employees | 82 | KR#1,793/2,421 Sec#148/231 |
| Value | ||
| P/B | 5.16x | KR#2,251/2,421 Sec#192/231 |
| P/S | 150.54x | KR#2,399/2,421 Sec#216/231 |
| FCF Yield | -7.18% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -70.05% | KR#2,320/2,421 Sec#208/231 |
| ROA | -63.45% | KR#2,378/2,421 Sec#219/231 |
| Op. Margin | -1246.31% | KR#2,382/2,421 Sec#214/231 |
| Revenue Growth | 116.74% | KR#70/2,421 Sec#13/231 |
| Earnings Growth | -558.53% | KR#1,309/2,421 Sec#91/231 |
| Financial Health | ||
| Debt Ratio | 10.39% | KR#152/2,421 Sec#31/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -20.67B KRW | KR#1,897/2,421 Sec#180/231 |
| Cash | 9.48B KRW | KR#1,726/2,421 Sec#146/231 |
| Current Ratio | 6.10x | KR#209/2,421 Sec#41/231 |
| Performance | ||
| 1Y Return | -14.81% | KR#1,105/2,421 Sec#71/231 |
| 1M Return | -12.33% | KR#2,178/2,421 Sec#180/231 |
| From 52W High | -77.11% | KR#2,316/2,421 Sec#208/231 |
| 1Y MDD | -77.62% | KR#2,252/2,421 Sec#202/231 |
| Trading | ||
| Volume | 14,656 shares | KR#1,752/2,421 Sec#172/231 |
| Trading Value | 465.9M KRW | KR#950/2,421 Sec#95/231 |
| Foreign Own. | 2.05% | KR#1,606/2,421 Sec#153/231 |
| Per Share | ||
| EPS | -4,348 KRW | KR—/2,421 Sec—/231 |
| BPS | 6,207 KRW | KR#1,338/2,421 Sec#92/231 |
Company Info
동사는 1999년 유전자 교정 플랫폼 사업을 위해 설립되어 2021년 코스닥 시장에 상장함. ZFN, TALEN, CRISPR/Cas9 등 유전자가위를 독자 개발한 세계 유일 기업으로 CRISPR 유전자가위의 진핵세포 작동을 세계 최초로 입증한 특허 보유, 특허 388건 확보함. 유전자 교정 플랫폼 기술의 원천특허 기반으로 특허 수익화, 치료제 및 종자 관련 연구개발을 진행하며 질병 없는 건강 및 풍요로운 삶을 목표로 하고 있음. 툴젠는 1999년에 설립되었으며 서울특별시 강서구에 본사를 두고 있습니다.